Chemotherapy-related thrombocytopenia
Conditions
Interventions
single:Three dose levels of rhTPO300u/Kg+ hytrebopag (2.5mg, 5mg, 7.5mg) were used
Sponsors
The 3rd people's hospital of Zhengzhou
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) patients with malignant solid tumors confirmed by pathology; (2) required chemotherapy, expected to require 4-6 cycles; (3) PS score 0-1; (4) age of 18-75 years old; (5) normal function of heart, liver and kidney; (6) The lowest platelet count =25×109/L in the previous chemotherapy cycle was given conventional treatment, but the lowest platelet count =25×109/L occurred again in the current chemotherapy cycle.
Exclusion criteria
Exclusion criteria: (1) The expected survival time was less than 3 months; (2) d1, 8 days chemotherapy; (3) patients with thrombocytopenia caused by bone marrow infiltration; (4) patients with thrombocytopenia caused by hematological diseases; (5) clinical evidence of active bacterial or fungal infection or active viral infection; (6) poor compliance, unable to receive chemotherapy on time or participate in the setting of regimens; (7) platelet raising drugs other than rhTPO+ ztrombopag were used during treatment; (8) Mental disorders.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Duration of platelet count < 50×109;The number of days for platelet recovery to more than 100×109/L; | — |
Countries
China
Contacts
Public ContactTiandong Kong
the 3rd people's hospital of Zhengzhou
Outcome results
None listed